Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil.
OBJECTIVE
The effect of gemfibrozil is mediated by the activation of peroxisome proliferator-activated receptor alpha (PPAR alpha). The objective of this study was to determine whether the lipid response to gemfibrozil therapy is influenced by the PPAR alpha-L162V polymorphism.


METHODS
Sixty-three abdominally obese men were randomly assigned to a 6-month-intervention program with either receiving a placebo (N = 31) or gemfibrozil (N = 32).


RESULTS
In response to gemfibrozil therapy, L162-homozygotes exhibited a 5.5% increase in high-density lipoprotein 2 cholesterol (HDL(2)-C) levels compared with a 50.0% increase among carriers of the V162 allele (P = 0.03).


CONCLUSIONS
These results suggest that the HDL(2)-C response to gemfibrozil is modulated by the PPAR alpha-L162V polymorphism.
Bossé
Yohan
Y
Lipid Research Center, CHUL Research Center, Laval University, Sainte-Foy, Quebec, Canada.
Pascot
Agnès
A
Dumont
Martine
M
Brochu
Martin
M
Prud'homme
Denis
D
Bergeron
Jean
J
Després
Jean-Pierre
JP
Vohl
Marie-Claude
MC
D000005:Abdomen; D000328:Adult; D008076:Cholesterol, HDL / Q000097:blood*; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D011110:Polymorphism, Genetic; D018160:Receptors, Cytoplasmic and Nuclear / Q000097:blood* / Q000235:genetics; D014157:Transcription Factors / Q000097:blood* / Q000235:genetics
D008076:Cholesterol, HDL; D008055:Lipids; D008074:Lipoproteins; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D015248:Gemfibrozil